For advanced HR-positive breast cancer in premenopausal women, OFS is essential to induce a postmenopausal state, especially when using targeted medications like cyclin-dependent kinase 4/6 (CDK4/6) inhibitors alongside endocrine therapy. This evidence concerns the gene CDK4 and breast cancer.